US investors sought for wearable medical therapy device company The Diabetic Boot Company trading as PulseFlow Technologies

Tools

January 28, 2016 12:30 PM Eastern Standard Time

LONDON--(BUSINESS WIRE)--The Diabetic Boot Company t/a PulseFlow Technologies (DBC) earned a place as one of the UK's highest crowd funded companies of 2015 after raising approx. £1.75m via Syndicate Room led by major life science investor Jim Mellon. The boot strap startup goes from strength to strength since receiving Food and Drug Administration (FDA) approval to market PulseFlowDF® (a therapeutic medical device designed to improve diabetic foot ulcer healing) in the United States. However, the vast commercial opportunity in the US requires an injection of working capital to enhance the company's newly established US operations and ensure the anticipated high levels of demand can be met for this exciting limb salvage technology.

Diabetic foot ulcers are multi-faceted wounds requiring a diverse approach to treatment. PulseFlowDF combines the proven benefits of pressure redistribution in well-designed footwear, with intermittent plantar compression ensuring oxygen-rich blood flows around the wound. Listed on the UK National Health Service (NHS) Supply Chain catalogue and available to any NHS patient, PulseFlowDF has a patient compliance monitor built in to correlate healing to wear times. Studies carried out on patients by Richard Leigh, Consultant Podiatrist at University College London Hospital NHS Foundation Trust have yielded positive results. Potential investors seeking long term ROI are reassured by DBC's board members impressive clinical-to-business background.

CEO Les Lindsay, who sold his house to fund initial product development says, "PulseFlowDF is already helping to save lower limbs from amputation in patient trials which is incredible considering that globally, someone suffers a diabetes related amputation every 20 seconds usually due to a diabetic wound that will not heal."

The World Health Organization (WHO) projects that diabetes will be the 7th leading cause of death by 2030. Complications developed through the disease such as lower limb neuropathy can lead to an untreatable foot ulcer and amputation – accounting for a vast part of healthcare costs for surgery and aftercare. World leading podiatric surgeon and champion of PulseFlowDF, David Armstrong, Director of Southern Arizona Limb Salvage Alliance (SALSA) and Professor of Surgery at The University of Arizona writes on his blog Diabetic Foot Online that 5% of people with a new diabetic foot ulcer die in the 1st year (42% in 5 years).

The world is facing an epidemic of lower limb circulation problems for which there are significant unmet clinical answers. PulseFlowDF offers good value to healthcare managers by delivering non-invasive therapy and increased patient motivation through wearable (non-stigmatised) treatment.

Interested financiers, contact www.pulse-flow.net

Ed note:

The Telegraph
Financial Times
Contacts
PulseFlow Technologies
Les Lindsay (CEO)
les.lindsay@pulse-flow.net
+44(0)1296-678-596